https://charts.traderzeitung.de/phases/US83422E2046
string(1398) "{"isin":"US83422E2046","name":"Solid Biosciences Inc","stock_id_xnas":7874995,"stock_id_xnys":null,"generated_at":"2026-08-21 23:33:00","days":[{"date":"2026-08-19","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":9.75,"close_at":"2026-08-19 21:59:00","complete":true,"perf_pct":null},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]},{"date":"2026-08-20","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":9.095,"close_at":"2026-08-20 21:59:00","complete":true,"perf_pct":-6.7179},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]},{"date":"2026-08-21","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":9.315,"close_at":"2026-08-21 21:59:00","complete":true,"perf_pct":2.4189},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":false,"perf_pct":null}]}]}"
Solid Biosciences Aktie News & Nachrichten

Solid Biosciences Aktie News & Nachrichten

[WKN: A3DXEC | Symbol: SLDB]
Realtimekurs
   
Vorbörsliche Indikationen
Regulärer Handel
Nachbörslicher Handel

Artikel aus der Redaktion der Trader-Zeitung

TOP-5-Kursziele der Analysten am 10.09.25

EssilorLuxottica S.A. [FR0000121667] Barclays nimmt die Aktie mit "Overweight" und Ziel 305 Euro in...

Solid Biosciences Inc. (SLDB) - Ein Blick in die Zukunft der Gentherapie bei neuromuskulären und kardialen Erkrankungen

Solid Biosciences Inc. (SLDB) positioniert sich als ein aufstrebendes Biotechnologieunternehmen, das...

  • 1
MT Newswires 07.08.2026 17:03 Uhr

Wedbush senkt Kursziel für Solid Biosciences von $16 auf $15, belässt Rating auf Outperform

11:02 AM EDT, 07.08.2026 (MT Newswires) -- Solid Biosciences (SLDB) hat laut von FactSet befragten Analysten ein durchschnittliches Rating von Kaufen